Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TIL-ACT and Nivolumab Rescue in Metastatic Melanoma
NCT03475134Phase 1Completed
- Sponsor
- Lausanne University Hospital
- Start
- Feb 2018
- Primary completion
- Feb 2021
- Modality
- Monoclonal Antibodies, Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of GC101 TIL + pembrolizumab in melanoma, sponsored by Lausanne University Hospital. Primary endpoints: Feasibility of TIL-ACT - successful Rapid Expansion Protocol (REP) at Day 0, Feasibility of TIL-ACT - successful infusion at Day 0 and 1 more. Started Feb 2018; status: completed.
02
Drugs
GC101 TIL + pembrolizumab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT03475134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03475134.